State Street SPDR S&P Biotech ETF
129 hedge funds and large institutions have $1.68B invested in State Street SPDR S&P Biotech ETF in 2014 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 35 increasing their positions, 55 reducing their positions, and 8 closing their positions.
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
13.2% more ownership
Funds ownership: 404.03% → 417.23% (+13%)
5% more capital invested
Capital invested by funds: $1.6B → $1.68B (+$84M)
5% more funds holding
Funds holding: 123 → 129 (+6)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
36% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 55
42% less call options, than puts
Call options by funds: $51.9M | Put options by funds: $90M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$100M |
| 2 |
JP Morgan Chase
New York
|
+$15.3M |
| 3 |
CCMH
Cornerstone Capital Management Holdings
New York
|
+$5.92M |
| 4 |
U
UBS
Zurich,
Switzerland
|
+$4.6M |
| 5 |
LCS
Levin Capital Strategies
New York
|
+$2.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$30.1M |
| 2 |
SCM
Sandler Capital Management
New York
|
-$11.3M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$7.01M |
| 4 |
TH
Timber Hill
Greenwich,
Connecticut
|
-$4.9M |
| 5 |
Jane Street
New York
|
-$2.68M |
XBI Hedge Fund Activity: Q3 2014 in Review
129 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q3 2014, worth a combined $1.68B — up 5.3% from $1.6B a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new XBI positions and 8 closed out — a net gain of 7 holders — while 35 added to existing stakes and 55 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $100M. The largest seller was Citigroup, cutting an estimated $30.1M.
- 129 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q3 2014, up from 123 in Q2 2014.
- Funds reported $1.68B of State Street SPDR S&P Biotech ETF stock for Q3 2014, up 5.3% quarter-over-quarter.
- 15 funds opened new State Street SPDR S&P Biotech ETF positions in Q3 2014 and 8 closed out, a net change of +7 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q3 2014 was Goldman Sachs, an estimated $100M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q3 2014 was Citigroup, an estimated $30.1M sold.
Based on aggregated 13F filings for Q3 2014.